Puma Biotechnology Inc
Veridion Score
Composite trend over time
Why is PBYI moving today?
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for PBYI.
PBYI insider activity
Puma Biotechnology Inc
No multi-insider buying cluster in the last 90 days
Net selling: -$1.3M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-15 | 2026-06-12 | WILSON TROY EDWARD | Insider | sell | $7.20 | 10,800 | 59,750 | $78K | SEC Form 4 |
| 2026-06-15 | 2026-06-12 | Stuglik Brian M | Insider | sell | $7.20 | 8,100 | 113,858 | $58K | SEC Form 4 |
| 2026-06-15 | 2026-06-12 | Senderowicz Adrian | Insider | sell | $7.20 | 27,000 | 27,000 | $194K | SEC Form 4 |
| 2026-06-15 | 2026-06-12 | Dorval Allison | Insider | sell | $7.20 | 11,610 | 90,780 | $84K | SEC Form 4 |
| 2026-06-15 | 2026-06-12 | MOYES JAY M | Insider | sell | $7.22 | 22,000 | 58,322 | $159K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 14 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moPBYI contract awards, year to date.
Public federal awards linked to this ticker.
PBYI lobbying filings, year to date.
Registered lobbying filings matched to Puma Biotechnology Inc.